Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Fossils from China show complex life evolved millions of years earlier than once thought - 2The most effective method to Begin Your Excursion in Gold Venture
- 3Can humans have babies in space? It may be harder than expected
- 4‘Everybody Loves Raymond: 30th Anniversary Reunion’ premiere date: How to watch, channel, time, cast and more
- 5Winter virus season so far is not too bad, but doctors worry about suffering to come
- The Hybrid Volkswagen ID. ERA 9X Will Become the Brand’s New Flagship in China
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- Volkswagen in talks with defence firms on use of Germany plant: CEO
- Vote In favor of Your Favored Pet Consideration Administration
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- Air New Zealand cuts flights and hikes fares as fuel prices surge
- Shrewd Home Gadgets to Save Energy
